Juno is led by a management team with diverse backgrounds and talents, with the common goal of revolutionizing medicine through developing a broadly applicable cell-based platform.

Hans Bishop

President & CEO

Juno Therapeutics Hans Bishop


Hans Bishop is one of our company’s co-founders and has served as Chief Executive Officer since Juno’s inception. He served as an Executive in Residence at Warburg Pincus, a global private equity firm with significant investment experience in the pharmaceutical and healthcare industries. Prior to this, he acted as Executive Vice President and Chief Operating Officer for Dendreon, a Seattle-based biotechnology company that develops immunotherapy products used in cancer treatment. He has served as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. Mr. Bishop previously held various positions at Glaxo Wellcome and SmithKlineBeecham. Mr. Bishop earned a B.S. in chemistry from Brunel University in London.

Steve Harr, M.D.

CFO & Head of Corporate Development

Juno Therapeutics Steve Harr


Steven D. Harr is our Chief Financial Officer and Head of Corporate Development and joined Juno in April 2014. Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley from May 2010 until he joined Juno. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and Co-Head of Global Healthcare Research. Dr. Harr received a B.A. in Economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.

Sunil Agarwal, M.D.

President, Research and Development


Sunil Agarwal, M.D., is our President of Research and Development and joined Juno in April 2017. Previously, Dr. Agarwal was Chief Medical Officer and Executive Vice President at Ultragenyx. Prior to his tenure at Ultragenyx, Dr. Agarwal worked in a number of senior leadership roles at Genentech, Inc., most recently as Senior Vice President, Global Development Head, Ophthalmology, Metabolism, Neuroscience, Immunology and Infectious Diseases. He was responsible for the development of programs in these areas from proof of concept (PoC) through Phase IV. He has led global approvals of multiple therapies and successfully built and led large global development organizations in multiple geographies. Dr. Agarwal received his bachelor of science in Neuro-Biology at Cornell University and earned his medical degree from Tufts University School of Medicine. He completed his residency at Children’s National Medical Center, Washington, D.C., and subsequently joined the faculty at George Washington University School of Medicine.

Hyam Levitsky, M.D.

EVP, Chief Scientific Officer



Hyam (“Hy”) Levitsky is our Executive Vice President, Chief Scientific Officer and joined Juno in May 2015.  Prior to joining Juno, Dr. Levitsky held the position of Head of Cancer Immunology Experimental Medicine at Roche Pharma Research and Development in Basel, Switzerland.  Prior to that, Levitsky served as a Professor of Oncology, Medicine and Urology at The Johns Hopkins University School of Medicine, and was also an active staff member in Oncology and Medicine at The Johns Hopkins Hospital. Dr. Levitsky received a B.S.  from the University of Pennsylvania School of Engineering and Applied Science and an M.D. from The Johns Hopkins School of Medicine and did his internship and residency in internal medicine on the Osler Medical Service at Johns Hopkins Hospital, rising to become Assistant Chief of Service. He trained in Medical Oncology as a Senior Clinical Fellow at Johns Hopkins Oncology Center, became Assistant Professor of Oncology in 1991, rising to full Professor in 2001, and taught in the School of Medicine until 2011. His areas of expertise include Oncology, Immunology, Hematologic Malignances / Bone Marrow Transplantation (serving as Scientific Director of the George Santos Bone Marrow Transplant Program), Cellular and Molecular Medicine, and Pathobiology.  Dr. Levitsky is also a founding Executive Committee member of the Cancer Immunotherapy Consortium of the Cancer Research Institute.  He was a Stohlman Scholar of the Leukemia and Lymphoma Society of America (LLS) and a member of the American Society for Clinical Investigation (ASCI).  He is also an active member of the American Association of Cancer Research, the American Society of Hematology, and is one of a select group of immunologists serving on review panels for both the LLS SCOR program and the Cancer Prevention and Research Institute of Texas. He was a founding member of MIATA (Minimal Information About T cell Assays), advises the FDA on cancer immunotherapy issues and serves on the External Scientific Advisory Board of the Pasteur Institute’s Center for Human Immunology, has consulted on a number of industry scientific advisory boards and contributes and provides editorial support to several prestigious cancer, immunology, scientific and medical publications.  Dr. Levitsky holds several patents.

Bob Azelby

EVP, Chief Commercial Officer


Robert (“Bob”) Azelby is our Executive Vice President, Chief Commercial Officer and joined Juno in November 2015. Prior to joining Juno, Bob was the Vice President and General Manager of Amgen’s Oncology Business Unit. He was also the Vice President of Amgen’s U.S. Oncology Sales team, one of the largest oncology sales teams in the United States. In addition, Bob was the Vice President of Amgen’s North American Commercial Effectiveness Unit, responsible for sales and marketing functions, including market research, forecasting, sales training, and sales operations. Bob garnered international experience as Amgen’s General Manager, Netherlands, responsible for all aspects of its commercial operations in that country. Bob held numerous sales and marketing positions, each with increasing responsibilities. Roles included project management, business development, regional sales management, and national marketing director. Before joining Amgen, Bob was Chief Operating Officer for a venture-capital-backed early-stage company specializing in catastrophic event medical management. Bob also held the position of Chief Financial Officer for a subsidiary of Oxford Health Plans and was also a Professional Sales Representative for GlaxoWellcome. Bob received his undergraduate degrees in Economics and Religious Studies from the University of Virginia and his Master of Business Administration from Harvard University.

Corsee Sanders, Ph.D.

EVP, Head of Development Operations



Corsee Sanders is our Executive Vice President, Development Operations and joined Juno in January 2017. She is responsible for the planning, management, execution, analysis, and reporting of Juno’s clinical trials. Prior to joining Juno, Dr. Sanders was Senior Vice President and Head of Global Clinical Operations and Industry Collaborations at Roche Pharmaceuticals, where she also served as Head of Global Biometrics and Development Innovation. Previously, she worked in a number of senior leadership roles at Genentech, Inc., where she was instrumental in the development of some of Genentech’s most successful products, including Herceptin and Avastin. At Genentech, her responsibilities covered a range of functions, including biostatistics, epidemiology, health economics and outcomes research, data management, medical writing, information technology, and biosample management. Dr. Sanders holds bachelor’s and master’s degrees in statistics from the University of the Philippines, and received a master’s degree and doctorate in statistics from the Wharton School at the University of Pennsylvania.

Mark Gilbert, M.D.

SVP, Chief Medical Officer

Juno Therapeutics Mark Gilbert


Mark J. Gilbert is our Chief Medical Officer and joined Juno in March 2014. Prior to joining Juno, Dr. Gilbert served as an interim CMO or consultant in strategic drug development and portfolio management in medical oncology for several US biotech and pharmaceutical companies. Previously, Dr. Gilbert served as Vice President and Head Global Clinical Development, Therapeutic Area Oncology, at Bayer Schering Pharmaceuticals. Prior to Bayer Schering, he held several executive positions with Berlex Pharmaceuticals and its parent company Schering, AG, mostly as Vice President and Head of Global Medical Development Group, Oncology. Dr. Gilbert joined Berlex from Immunex, where his responsibilities included development and medical affairs for Leukine and Mitoxantrone in hematology, oncology, Crohn’s disease, and multiple sclerosis. Dr. Gilbert received a B.S. in Biochemistry from the University of Iowa and his M.D. from the University of Iowa Medical School and trained in internal medicine, infectious disease, and medical oncology at the University of California, San Francisco, and the University of Washington, respectively. Prior to his executive positions in biotech and oncology companies, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington and trained in the laboratory of Dr. Phil Greenberg, one of our scientific co-founders.

Barney Cassidy, J.D.

General Counsel & Secretary

Juno Therapeutics Barney Cassidy


Barney Cassidy is our General Counsel & Secretary and joined Juno in January 2014. Prior to joining Juno, Mr. Cassidy served in various roles at Tessera Technologies, Inc., a semiconductor packaging company, from November 2008 to July 2013, including as its Executive Vice President, General Counsel, and Secretary, and as President of Tessera Intellectual Property Corp. He served in various roles at Tumbleweed Communications Corp., a provider of secure messaging and secure file transfer solutions, from May 1999 to September 2008, including as its Senior Vice President, General Counsel, and Secretary. Mr. Cassidy practiced law at Wilson Sonsini Goodrich & Rosati, Professional Corporation, from August 1992 to May 1999, and at Skadden, Arps, Slate, Meagher & Flom LLP from September 1989 to July 1992. Mr. Cassidy received a B.A. in Philosophy from the Jesuit House of Studies, Loyola University, New Orleans, an M.A. in Philosophy from the University of Toronto, and a J.D. from Harvard Law School. He also completed the Executive Education Program for Growing Companies at Stanford Graduate School of Business.

Elizabeth Smith

SVP, Regulatory and Quality Assurance

Juno Therapeutics Elizabeth Smith


Elizabeth Smith is our Senior Vice President, Regulatory and Quality Assurance, and joined Juno in November 2013. Ms. Smith has over 20 years of experience in the field of regulatory affairs, quality, and manufacturing, with an emphasis on biologics and advanced cellular therapies in oncology. Most recently, Ms. Smith served as the Vice President of Regulatory Affairs at Dendreon and led the regulatory efforts resulting in FDA licensure of Provenge, the first approved active cellular therapy for the treatment of cancer. Prior to Dendreon, Ms. Smith held regulatory and manufacturing positions at Genentech and Immunex. She holds B.A. in Biology from Central Washington University.

Andy Walker, Ph.D.

SVP, Manufacturing

Juno Therapeutics Andy Walker


Andrew Walker is our Senior Vice President, Manufacturing, and joined Juno in April 2014. Prior to joining us, Dr. Walker served in senior leadership roles at CMC Biologics, a contract biologics drug development and manufacturing organization. While at CMC Biologics, Dr. Walker’s roles included serving as the Head of the GMP Manufacturing Department, where he led the design, start-up, and operation of multiple GMP manufacturing facilities. Dr. Walker also served as Head of the Process Development organization where he oversaw all aspects of drug development from cell line creation, upstream and downstream process development, analytical and formulation development, and process transfer and process validation. Over the course of his career, Dr. Walker has worked on the development and manufacturing of approximately 50 different biologic drug candidates.

Andy earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from the University of Washington. Andy also has a Management of Technology certificate from the UC Berkeley Haas School of Business.

Lothar Germeroth, Ph.D.

SVP, Managing Director


Lothar Germeroth is our Senior Vice President, Managing Director Juno Therapeutics GmbH, and joined Juno through the acquisition of Stage Cell Therapeutics in May 2015. Dr. Germeroth has over 25 years of experience in the field of biotechnology. Most recently, Dr. Germeroth served as the CEO at IBA GmbH and the COO at Stage Cell Therapeutics GmbH, and served eight years as CEO in three different German Biotech companies (Jerini BioTools GmbH, Chemotopix GmbH, Cytos Proteome Therapeutics GmbH) and as Chief Business Officer at Cytos Biotechnology AG in Switzerland. Dr. Germeroth studied chemistry in Frankfurt/Main and obtained his PhD in Biochemistry in the department of Nobel Prize Laureate Professor Hartmut Michel at the Max-Planck Institute of Biophysics in Frankfurt.

Robin Andrulevich

SVP, People

Juno Therapeutics Robin Andrulevich


Robin Andrulevich is our SVP of People and joined Juno in October 2014. Ms. Andrulevich has over twenty years of experience in Human Resources at high-growth companies. Most recently, Ms. Andrulevich served as the Talent Director for the early-stage technology venture capital firm, Madrona Venture Group, where she worked with investors and over fifty startups on all organizational development and talent needs. Ms. Andrulevich also held several key, senior leadership human resources and talent roles at Amazon and worked closely with its management team to significantly scale the company’s growth. A graduate of the University of Connecticut, with a B.A. in Communications Science, Ms. Andrulevich also attended Barnard College and Columbia University.